Title |
Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial
|
---|---|
Published in |
Trials, October 2014
|
DOI | 10.1186/1745-6215-15-412 |
Pubmed ID | |
Authors |
Jacqueline Detert, Pascal Klaus, Joachim Listing, Vera Höhne-Zimmer, Tanja Braun, Siegfried Wassenberg, Rolf Rau, Frank Buttgereit, Gerd R. Burmester |
Abstract |
Osteoarthritis (OA) is a heterogeneous group of conditions with disturbed integrity of articular cartilage and changes in the underlying bone. The pathogenesis of OA is multifactorial and not just a disease of older people. Hydroxychloroquine (HCQ) is a disease-modifying anti-rheumatic drug (DMARD) typically used for the treatment of various rheumatic and dermatologic diseases. Three studies of HCQ in OA, including one abstract and one letter, are available and use a wide variety of outcome measures in small patient populations. Despite initial evidence for good efficacy of HCQ, there has been no randomized, double-blind, and placebo-controlled trial in a larger patient group. In the European League Against Rheumatism (EULAR), evidence-based recommendations for the management of hand OA, HCQ was not included as a therapeutic option because of the current lack of randomized clinical trials. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 25% |
Unknown | 3 | 75% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 1% |
Italy | 1 | 1% |
Unknown | 72 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 11 | 15% |
Student > Master | 10 | 14% |
Other | 6 | 8% |
Student > Ph. D. Student | 5 | 7% |
Student > Postgraduate | 4 | 5% |
Other | 13 | 18% |
Unknown | 25 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 27 | 36% |
Nursing and Health Professions | 5 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
Computer Science | 2 | 3% |
Economics, Econometrics and Finance | 2 | 3% |
Other | 5 | 7% |
Unknown | 29 | 39% |